MedTrace Logo

Study in Elderly Patients With Early Breast Cancer (ICE)

NCT00196859 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1500

Last updated 2014-07-17

No results posted yet for this study

Summary

This trial is done to determine the role of adjuvant chemotherapy with capecitabine in patients ≥ 65.

Conditions

Interventions

DRUG

Ibandronate, Capecitabine

Ibandronate 50 mg p.o. daily or 6 mg i.v., q4W, 2yrs plus Capecitabine 2000 mg/m2 days 1-14 q d22 x6

DRUG

Ibandronate

Ibandronate 50 mg p.o. daily or 6 mg i.v., q4W, 2yrs

Sponsors & Collaborators

Principal Investigators

  • Ulrike Nitz, MD · Evangelisches Krankenhaus Bethesda, Mönchengladbach

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
65 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-06-30
Primary Completion
2014-01-31
Completion
2014-01-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00196859 on ClinicalTrials.gov